DYN — Dyne Therapeutics, Inc.
7 mentions in the last 24 hours · 0.03% of all mentions
Why people talked about DYN (2026-11-05)
- Dyne Therapeutics reported Q3 2026 financial results showing a widened loss due to higher R&D costs.
- The company reported an EPS of -$1.06, missing estimates, with zero revenue for the quarter.
- Cash runway extends into Q2 2028, and the results were announced via Form 8-K on November 5, 2026.
| Bluesky | 4 | community |
| GDELT | 2 | news |
| SEC EDGAR 8-K | 1 | filings |